A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders (iNCGS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is a multicenter, open label, observational, post marketing surveillance study of NutropinAq® in Austria, France, Germany, Italy, Spain, Romania and United Kingdom to collect long-term safety and effectiveness information on NutropinAq® during treatment of paediatric growth disorders.
Condition or disease
Growth Hormone Disorders
The objective of this study is to collect long term safety and effectiveness information on Ipsen's growth hormone (GH) NutropinAq® regarding treatment of paediatric growth disorders for which GH is indicated.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children treated with NutropinAq in the specialised paediatric endocrinology centres
Children of either sex who are treated with NutropinAq® for the treatment of growth failure
Patients who are willing to comply with follow-up appointments throughout study participation
Written informed consent signed by both parents or by the liable parent or by the legal guardian when applicable, and by the child when applicable